Loss of ATG14 in Mouse Livers Triggers Four Simultaneous Cell Death Pathways

The liver is constantly doing damage control. Hepatocytes rely on autophagy - the cellular process of digesting damaged components - to maintain order under constant metabolic stress. When autophagy fails, the consequences compound quickly. A study published in eGastroenterology provides the most detailed account yet of what happens when one critical autophagy regulator, a protein called ATG14, is removed specifically from liver cells.

The answer is more severe than expected. Mice lacking ATG14 in hepatocytes did not simply develop impaired autophagy. They activated four distinct regulated cell death programs simultaneously, developed massive liver enlargement, and progressed rapidly from cellular injury to fibrosis. A Western-diet challenge accelerated every aspect of the damage. The findings position ATG14 not as one autophagy factor among many but as a central suppressor of multiple lethal pathways at once.

A fivefold increase in liver mass and cascading injury markers

Even under normal dietary conditions, mice engineered to lack ATG14 in hepatocytes (Atg14 HepKO) developed severe hepatomegaly, with liver weight increasing nearly fivefold. Serum levels of ALT and AST surged markedly. The protein HNF4-alpha, a master regulator of hepatocyte identity, decreased, indicating that cells were losing their specialized character.

Simultaneously, the livers showed widespread oxidative stress. Reactive oxygen species levels rose. Lipid peroxidation markers increased. DNA damage markers accumulated. Expression of antioxidant enzymes including SOD1, SOD2, SOD3, and catalase dropped significantly. Electron microscopy revealed structurally abnormal mitochondria with disorganized inner membranes and reduced expression of respiratory chain complexes I, III, and V.

Four cell death pathways activated at once

The most significant finding is the breadth of cell death programs ATG14 appears to hold in check. The researchers documented simultaneous activation of apoptosis (increased cleaved caspase-3, elevated Bax, Apaf1, and Ddit3), necroptosis (elevated RIPK3 and MLKL), pyroptosis (increased NLRP3, AIM2, GSDMD, GSDME, and cleaved IL-1-beta), and PANoptosis (upregulation of ZBP1, RIPK1, IRF1, STAT1, and caspase-8).

Each pathway represents a distinct mechanism of regulated cell death with different inflammatory consequences. Activating all four at once creates an inflammatory cascade that compounds cellular injury well beyond the initial autophagy defect. Immunofluorescence showed pyroptosis markers concentrated in hepatocytes while inflammasome components were elevated mainly in infiltrating macrophages, indicating a coordinated multi-cell-type response.

Western diet triples collagen accumulation

When Atg14 HepKO mice were exposed to a Western diet, every aspect of the disease worsened. Macrophage infiltration increased. TNF-alpha production rose. NF-kB pathway activation intensified. Hydroxyproline levels tripled, indicating three times as much extracellular matrix accumulation as under standard dietary conditions. Transcriptomic analysis confirmed major upregulation of inflammatory, fibrotic, and cell-death-related gene networks alongside suppression of fatty acid oxidation and oxidative phosphorylation pathways.

NRF2 as an unexpected link between autophagy failure and cell death

Cell-based experiments using human hepatoma cells provided mechanistic clarity. Knocking down ATG14 sensitized cells to pyroptosis with strong NLRP3 activation. Knocking down other autophagy genes - ATG5 and ATG7 - produced similar cell death signatures, confirming that ATG14's effects operate through its core autophagy function. Strikingly, knocking down NRF2 - normally considered a protective antioxidant regulator - actually reduced the cell death triggered by autophagy deficiency, placing NRF2 downstream of autophagy impairment as a paradoxical amplifier of damage in this context.

Limitations and therapeutic implications

The study was conducted entirely in mouse models and hepatoma cell lines. Mouse liver physiology differs from human liver physiology in important ways, particularly regarding lipid metabolism and inflammatory signaling. Whether ATG14 deficiency in human hepatocytes produces an equivalent multi-pathway response remains to be demonstrated in human tissue systems. The Western-diet model used here represents an accelerated metabolic challenge that does not perfectly replicate the gradual development of metabolic-associated steatotic liver disease in humans.

Those caveats aside, the mechanistic picture is unusually coherent. ATG14 emerges as a protein that simultaneously restrains multiple lethal programs, maintains mitochondrial integrity, preserves hepatocyte identity, and suppresses inflammatory activation. As metabolic liver diseases continue to rise globally, therapeutic strategies that restore ATG14 activity or compensate for its loss represent a potentially productive research direction.